Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2024

Annual Industry Ranking And Forecast

VIEW NOW

Featured Stories


Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine

Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.

Clinical Trials Vaccines Drug Approval Standards

Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants

The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.

Business Strategies Clinical Trials Neurology

C4XD Delisting Highlights Funding Frustration For UK Biotechs

The Manchester-based group has had enough of being undervalued in the public markets and is going private again.

Financing Business Strategies United Kingdom

Asia Spotlight

Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?

Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.


Commercial Legislation

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics

Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics. 

Executive Changes Leadership

Stock Watch: Acadia And Amylyx Trial Failures Were No Shock

The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.

Stock Watch Clinical Trials

Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon

Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.

Financing Growth

Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
Interviews

CinFina Pushes Early Work In Obesity In Hopes Of A Deal

Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.

StartUps and SMEs Metabolic Disorders

ITF Has A Fight On Its Hands In Duchenne

The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.

Approvals Commercial

Novartis Measures Malaria Success On Impact Rather Than Money

The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.

Rwanda Market Access

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Financing ImmunoOncology
See All
Graphics

Bangers In MASH: How Rezdiffra's Rivals Stack Up

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

Clinical Trials Liver & Hepatic

A Visual Trip Through The Psychedelic Pipeline

An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors. 

Clinical Trials Research & Development

Weighty Matters: The Obesity Market Now… And In Years To Come

INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.

Clinical Trials Commercial

Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

Companies Deals
See All
Recent Stories

Mustang Bio Enters Race For CAR-T In Autoimmune Disease

The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.

ImmunoOncology Business Strategies

Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024

Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.

Clinical Trials Drug Approval Standards

Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics

Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics. 

Executive Changes Leadership

Israel's Gamida Cell Survives By Selling To Lender

Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.

M & A Financing

Stay Or Exit? Global Health Players Ponder New China Trajectory

It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.

China Business Strategies

Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout

The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.

Deals Companies

Vertex Joins Regulus In Kidney Disease Therapy Hunt

The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.

Companies Clinical Trials

Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?

Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.

Commercial Legislation

China Biotech IPO Drought Lingers But HK Sees First Of 2024

Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.

Financing China

With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy

The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.

Approvals Launches

Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results

The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.

Cancer ImmunoOncology

Viking’s Oral Weight-Loss Drug Shows Early Efficacy/Safety Promise

An oral formulation of the GLP-1/GIP analog VK2735 showed up to 5.3% reduction in body weight after four weeks in a Phase I study, with a nearly pristine safety and tolerability profile.

Clinical Trials Drug Approval Standards
UsernamePublicRestriction

Register